NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer’s Disease Models
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's DiseaseVancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen...